Status:
COMPLETED
Micrometastases in Axillary Lymph Nodes in Breast Cancer, Post-neoadjuvant Chemotherapy
Lead Sponsor:
Gangnam Severance Hospital
Conditions:
Micrometastases
Neoadjuvant Chemotherapy
Eligibility:
FEMALE
18-80 years
Brief Summary
This study aims to investigate the significance of minimal residual axillary disease following NAC, with a particular focus on micrometastases (ypNmi), in comparison to pathologic lymph node-negative ...
Detailed Description
This study aims to investigate the significance of minimal residual axillary disease following NAC, with a particular focus on micrometastases (ypNmi), in comparison to pathologic lymph node-negative ...
Eligibility Criteria
Inclusion
- Stage II or III primary breast cancer patients
- Patients who performed neoadjuvant chemotherpay
- Patients who underwent axillary lymph node dissection with or without sentinel lymph node biopsy
Exclusion
- Patients who performed upfront surgery
- De novo stage IV patients
Key Trial Info
Start Date :
September 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2018
Estimated Enrollment :
978 Patients enrolled
Trial Details
Trial ID
NCT06149884
Start Date
September 1 2006
End Date
February 28 2018
Last Update
November 29 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.